According to the firms, the partnership will use Illumina's platform for high-multiplex SNP-genotyping to develop diagnostics for gene variants that Decode has shown to be risk factors for various diseases.
Under the terms of the agreement, Illumina will gain access to disease-related biomarkers, which will be jointly validated as diagnostic panels. Illumina will market and sell these on its forthcoming BeadXpress platform, the partners said.
Illumina will also install its SNP-genotyping platform at Decode's labs in Iceland.
Initially, the companies will focus on the gene encoding leukotriene A4 hydrolase, which has been linked to heart attack; the gene encoding transcription factor 7-like 2, which is linked to type II diabetes; and the gene encoding BARD1, which is linked to breast cancer.
The companies will share development costs and split the profits from sales of the diagnostics tests.